 E25 |
 |
Adrenogenital disorders |
| |
| Includes |
adrenogenital syndromes, virilizing or feminizing, whether acquired or due to adrenal hyperplasia consequent on inborn enzyme defects in hormone synthesis
Female adrenal pseudohermaphroditism
Female heterosexual precocious pseudopuberty
Male isosexual precocious pseudopuberty
Male macrogenitosomia praecox
Male sexual precocity with adrenal hyperplasia
Male virilization (female)
|
| Excludes1 |
indeterminate sex and pseudohermaphroditism (Q56)
chromosomal abnormalities (Q90-Q99)
|
|
| |
 E25.0 |
|
Congenital adrenogenital disorders associated with enzyme deficiency |
| |
| Congenital adrenal hyperplasia | | 21-Hydroxylase deficiency | | Salt-losing congenital adrenal hyperplasia |
|
|
| |
| E25.8 |
|
Other adrenogenital disorders |
| |
| Idiopathic adrenogenital disorder |
| UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
|
|
|
| |
| E25.9 |
|
Adrenogenital disorder, unspecified |
| |
| Adrenogenital syndrome NOS |
|
|